Syndicate content

Archive - Jan 21, 2020

Date

OncoHost and RayBiotech Awarded $1 Million Grant from BIRD Foundation to Advance Precision Oncology for Patients Receiving Immunotherapy; Partnership Leverages Host Response Analysis to Predict Response to Therapy & Aid ID of New Drug Combinations

On Tuesday, January 21, 2020, OncoHost, a global leader in host response profiling for improved personalized cancer therapy, together with its partner RayBiotech, a leading life sciences company developing high-throughput protein detection technologies for biomarker discovery initiatives, announced that the companies have been awarded a $1 million grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation (https://www.birdf.com/). The BIRD Foundation supports cooperation between U.S. and Israeli companies for developing joint products or technologies in a wide range of technology sectors that are of mutual benefit to the U.S. and Israel. The grant will support OncoHost and RayBiotech's combined development and clinical validation of host response testing for the early prediction of treatment responsiveness in non-small-cell lung carcinoma (NSCLC) patients undergoing immunotherapy. It will also be used to further develop and implement an automated slide assistance platform (ASAP) for reducing the time of large-scale protein processing as part of a new joint service: host response enrichment for pharmaceutical companies. Both of these developments will contribute towards the enablement of personalized cancer therapy for patients. "The BIRD Foundation Board of Governors selected to support the project between OncoHost and RayBiotech on their mission to counteract therapy resistance in order to improve cancer treatment response," said Dr. Eitan Yudilevich, Executive Director of the BIRD Foundation.